A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4,317 women diagnosed in Denmark 1978-2006
Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum
Ovarian low-grade serous carcinoma: a comprehensive update
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube
Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
Wild-type tumor repressor protein 53 (Trp53) promotes ovarian cancer cell survival
Previous
Previous
2013
Next
Next